Candel Therapeutics (CADL) Income towards Parent Company (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Income towards Parent Company data on file, last reported at -$15.2 million in Q4 2025.

• For the quarter ending Q4 2025, Income towards Parent Company fell 91.63% year-over-year to -$15.2 million; the trailing twelve-month figure through Dec 2025 stood at -$81.4 million (down 15.18% YoY), and the FY2025 full-year result was -$109.6 million, down 83.05% from the prior year.
• Income towards Parent Company rose to -$15.2 million in Q4 2025, from -$23.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$4.7 million in Q1 2021 to a low of -$38.2 million in Q1 2022.
• A 5-year average of -$15.5 million and a median of -$10.3 million in 2023 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company plunged 717.13% in 2022 and jumped 73.19% in 2023, its largest moves.
• Tracing CADL's Income towards Parent Company over 5 years: stood at -$26.1 million in 2021, then soared by 67.34% to -$8.5 million in 2022, then fell by 22.77% to -$10.5 million in 2023, then climbed by 24.03% to -$7.9 million in 2024, then tumbled by 91.63% to -$15.2 million in 2025.
• Business Quant data shows CADL's Income towards Parent Company at -$15.2 million in Q4 2025, -$23.6 million in Q3 2025, and -$21.5 million in Q2 2025.